###begin article-title 0
Prognostic Significance of Multidrug Resistance Gene 1 (MDR1), Multidrug Resistance-related Protein (MRP) and Lung Resistance Protein (LRP) mRNA Expression in Acute Leukemia
###end article-title 0
###begin p 1
###xml 53 56 53 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 190 193 190 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 224 227 224 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 649 653 646 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 655 658 652 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 663 666 660 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 737 740 734 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 883 884 880 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 894 895 891 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 917 920 914 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 930 934 927 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 993 994 990 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1005 1006 1002 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1053 1056 1050 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 1061 1064 1058 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
###xml 846 854 <span type="species:ncbi:9606">patients</span>
###xml 1028 1036 <span type="species:ncbi:9606">Patients</span>
###xml 1228 1236 <span type="species:ncbi:9606">patients</span>
###xml 1369 1377 <span type="species:ncbi:9606">patients</span>
The prognostic significance of multidrug resistance (MDR) gene expression is controversial. We investigated whether multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression are associated with outcomes in acute leukemia patients. At diagnosis we examined MDR1, MRP and LRP mRNA expression in bone marrow samples from 71 acute leukemia patients (39 myeloid, 32 lymphoblastic) using nested RT-PCR. The expression of each of these genes was then expressed as a ratio in relation to beta-actin gene expression, and the three genes were categorized as being either 0, 1+, 2+ or 3+. MDR1, MRP and LRP mRNA expression was detected in 23.9%, 83.1% and 45.1%, respectively. LRP mRNA expression was significantly associated with resistance to induction chemotherapy in acute leukemia patients, and in the AML proportion (p=0.02 and p=0.03, respectively). MRP and high MDR1 mRNA expression was associated with poorer 2-yr survival (p=0.049 and p=0.04, respectively). Patients expressing both MRP and LRP mRNA had poorer outcomes and had worse 2-yr survival. The present data suggest that MDR expression affects complete remission and survival rates in acute leukemia patients. Thus, determination of MDR gene expression at diagnosis appears likely to provide useful prognostic information for acute leukemia patients.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 318 321 318 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
Drug resistance is a major obstacle in the successful treatment and an important cause of death in acute leukemia. Such resistance may be present before begining treatment or may develop during chemotherapy. Drug resistance that extends to structurally and functionally unrelated drugs is termed multidrug resistance (MDR) (1).
###end p 3
###begin p 4
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 651 652 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 820 821 820 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1045 1046 1045 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1391 1392 1391 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1469 1470 1469 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1471 1473 1471 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1489 1493 1489 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 1495 1498 1495 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 1503 1506 1503 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 1037 1043 <span type="species:ncbi:9606">humans</span>
Several molecular biological mechanisms have been identified as being associated with MDR (2). P-glycoprotein (PGP), also named P-170, is a product of the multidrug resistance 1 gene (MDR1) and is an ATP-dependent pump capable of expelling drugs out of cancer cells (3, 4). PGP is a transmembrane glycoprotein conferring cross-resistance to a variety of mechanistically and structurally unrelated cytotoxic drugs, such as anthracyclines, taxanes, vinca alkaloids and epipodophyllotoxins (5). Another protein, the multidrug resistance-related protein (MRP), is structurally similar to PGP and belongs to the same transmembrane transporter superfamily (6). The substrate specificity of MRP is similar to but more limited than that of PGP, and its normal physiological role may be detoxification of intracellular oxidants (5). In addition to these two proteins, a 110 kDa protein has been identified in a PGP-negative MDR lung cancer cell line. This protein was termed the lung resistance protein (LRP) and acts as a major vault protein in humans (7). Despite the identification of these proteins, the pathways that result in drug resistance in leukemic cells remain largely uncharacterized. New information regarding drug resistance mechanisms is likely to increase the chances of cure either through development of new drugs or by means of strategies that may modulate or reverse resistance (8). While drug resistance gene expression has been studied in acute leukemia (9-12), the value of MDR1, MRP and LRP gene expression as independent predictors of treatment success is still controversial.
###end p 4
###begin p 5
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 109 112 109 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
In the present study, we investigated whether outcomes in acute leukemia patients were associated with MDR1, MRP and LRP mRNA expression.
###end p 5
###begin title 6
MATERIALS AND METHODS
###end title 6
###begin title 7
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 7
###begin p 8
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 421 429 <span type="species:ncbi:9606">patients</span>
###xml 444 452 <span type="species:ncbi:9606">patients</span>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
###xml 526 534 <span type="species:ncbi:9606">patients</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
###xml 760 768 <span type="species:ncbi:9606">patients</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
###xml 976 984 <span type="species:ncbi:9606">patients</span>
###xml 1200 1208 <span type="species:ncbi:9606">patients</span>
###xml 1404 1412 <span type="species:ncbi:9606">patients</span>
###xml 1499 1507 <span type="species:ncbi:9606">patients</span>
###xml 1539 1547 <span type="species:ncbi:9606">patients</span>
###xml 1574 1582 <span type="species:ncbi:9606">Children</span>
###xml 1654 1662 <span type="species:ncbi:9606">patients</span>
The study involved 71 patients (34 males and 37 females) diagnosed with acute leukemia between January 1998 and January 1999. The median age of the patients was 30 yr (range, 3 months - 75 yr). Diagnosis and classification of acute leukemia was made according to the French-American-British (FAB) criteria and immunophenotype analyses. There were 39 acute myeloid leukemia (AML) and 32 acute lymphoblastic leukemia (ALL) patients. Among 39 AML patients, eleven patients had AML M1, 11 M2, 7 M3, 6 M4, 2 M5, 1 M6 and 1 M7. The patients were classified as being good prognosis group, intermediated prognosis group and poor prognosis group according to cytogenetic results. AML patients with t(8;21), t(15;17) and inv (16) were defined as "good prognosis group", patients with 5-, 7-, 5q-, 7q-, hyperdiploidy and multiple chromosomal abnormality were defined as "poor prognosis group", and the others were defined as the "intermediate prognosis group". Among AML patients, eight patients (t(8;21), 1; t(15;17), 7) were in good prognosis group, 20 (normal karyotype, 19; t(11;19), 1) in intermediate prognosis group and 12 (trisomy 8, 2; other complex abnormality, 10) in poor prognosis group. Among ALL patients, two were in good prognosis group, 11 in intermediate prognosis group and 19 in poor prognosis group. The induction chemotherapy regimen were cytarabine plus idarubicin (AI regimen) in adult AML patients and vincristine, prednisone, daunorubicin, L-asparaginase (VPDL regimen) in adult ALL patients. Newly diagnosed childhood ALL patients were treated according to Children's Cancer Group (CCG) 1881, 1882, 1891 or 1901 protocols. Childhood AML patients were treated according to BFM (Frankfurt Munster group) 83 protocols, including cyclophosphamide and prednisone. Clinical information was obtained by reviewing charts.
###end p 8
###begin title 9
Definition of disease phase and response
###end title 9
###begin p 10
###xml 234 242 <span type="species:ncbi:9606">patients</span>
Complete remission (CR) was defined as a cellularity of more than 20% with fewer than 5% blasts in the bone marrow (BM) after induction chemotherapy, and relapse as more than 5% blasts in the BM. The CR rate was calculated only using patients that underwent bone marrow analysis following initial diagnosis (64 cases).
###end p 10
###begin title 11
Semiquantitative RT-PCR
###end title 11
###begin p 12
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 158 161 158 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 210 213 210 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
Seventy one bone marrow aspirates collected in EDTA were obtained at the initial diagnosis. A COR-L23/R cell line was used as a positive control for MDR1 and LRP mRNA expression, and the HL60/Adr cell line for MRP mRNA expression. Negative controls included deionized RNAase-free water, and bone marrow aspirates obtained from patients with lymphoma without bone marrow involvement. beta-actin mRNA amplification was used as an internal control.
###end p 12
###begin p 13
Mononuclear cells were separated by density gradient centrifugation using Ficoll-Hypaque within 3 hr after bone marrow aspiration. Total cellular RNA was extracted using the RNeasy kit (Qiagen Inc., Valencia, CA, U.S.A.) according to the manufacturer's instructions.
###end p 13
###begin p 14
###xml 261 262 249 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1013 1014 961 962 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1316 1323 1261 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1485 1491 1430 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 1632 1636 1577 1581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 1638 1641 1583 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 1645 1648 1590 1593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 1801 1804 1743 1746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 366 369 <span type="species:ncbi:11866?0.5863095238095238|species:ncbi:12321?0.21726190476190477">AMV</span>
cDNA was synthesized using the First Strand cDNA Synthesis Kit for RT-PCR (Behringer Mannheim Inc, Germany). Total RNA (1 microg) was reverse transcribed in 20 microL reaction mixture (2 microL 10X Reaction buffer [100 mM Tris, 500 mM KCL, pH 8.3 and 25 mM MgCl2], 10 mM each of four dNTPs, 1.6 microg/microL random primers, 50 U/microL RNase inhibitor and 1 microL AMV Reverse Transciptase). The reaction was performed at 70℃ for 2 min and 42℃ for 60 min. MDR1, MRP and LRP mRNA amplifications were performed after heating the reaction mixture to 99℃ for 5 min. The first round of PCR reactions involved 30 cycles of: 1 min denaturing at 94℃, 1 min annealing at 64℃ and 2 min extension at 72℃ using a thermocycler (Perkin Elmer-Cetus, Wellesley, PA, U.S.A.). The PCR reactions were carried out in a final volume of 50 microL containing 2 microg cDNA, 10 pg/microL of each primer, 0.4 U/microL taq polymerase, 200 microM of each dNTP, 5 microL 10X buffer containing 500 mM KCl, 100 mM Tris (pH 8.3) and 25 mM MgCl2. The first round of PCR was followed by a second round of 20 cycles. Amplification of beta-actin mRNA (20 cycle PCR) was performed and the data obtained used to normalize any variations between samples (e.g. differences in concentration or quality of extracted RNA). PCR primer sequences are shown in Table 1. PCR products were electrophoretically separated on 2% agarose gels and visualized using ethidium bromide staining. The gel was photographed with Polaroid film (Fig. 1) and the film scanned into a computer (Sharp JX-330, Japan) for analysis. For semiquantitative measurements of mRNA, the relative ratios of MDR1, MRP or LRP mRNA expression to beta-actin mRNA expression was calculated using ImageMaster software (Pharmacia, Sweden). Following the determination of this ratio, MDR genes were classified as either not expressed (0), weakly expressed (ratio 0-0.7=1+), moderately expressed (ratio 0.7-1=2+), or strongly expressed (ratio >1=3+).
###end p 14
###begin title 15
Statistics
###end title 15
###begin p 16
###xml 173 174 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Data were analyzed using chi square or Fisher exact tests. Survival curves were plotted using the Kaplan-Meier method, and differences were analyzed using log-rank tests. A p value <0.05 was deemed to indicate a significant difference. All statistical analyses were performed using SPSS version 11.5 (SPSS, Chicago, IL., U.S.A.).
###end p 16
###begin title 17
RESULTS
###end title 17
###begin title 18
###xml 28 31 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
Expression rates, levels of MDR mRNA and cytogenetic results
###end title 18
###begin p 19
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 73 76 73 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 81 84 81 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 132 139 132 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 181 184 181 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 189 192 189 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 359 363 359 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 381 384 381 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 389 392 389 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 411 415 411 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 472 475 472 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 479 482 479 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 510 517 510 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 594 598 594 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 600 603 600 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 608 611 608 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 643 651 <span type="species:ncbi:9606">patients</span>
We found that the proportion of acute leukemia patients expressing MDR1, MRP and LRP mRNA was 23.9%, 83.1% and 45.1%, respectively (Table 2). In terms of leukemia categories, MDR1, MRP and LRP mRNA was expressed in 23.1%, 89.4% and 48.7% respectively of AML patients, and in 25.0%, 75.0% and 40.6% respectively of ALL patients. While fewer patients expressed MDR1 mRNA compared to MRP and LRP mRNA, the rate of MDR1 mRNA expression (3+) was higher than the rate of either MRP or LRP mRNA high expression (3+) (Table 2). Univariate analysis showed no correlation between cytogenetic results and MDR1, MRP and LRP mRNA expression in AML and ALL patients.
###end p 19
###begin title 20
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 21 24 21 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
Association of MDR1, MRP and LRP mRNA expression at diagnosis with the rate of complete remission, relapse and survival time
###end title 20
###begin p 21
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 214 217 214 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 250 251 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 304 307 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 354 357 354 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 399 402 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 534 538 534 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 542 545 542 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 612 616 612 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 620 623 620 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 643 650 643 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 653 657 653 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 659 662 659 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 666 669 666 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 772 775 772 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 835 838 835 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 475 482 <span type="species:ncbi:9606">patient</span>
###xml 560 568 <span type="species:ncbi:9606">patients</span>
###xml 633 641 <span type="species:ncbi:9606">patients</span>
LRP mRNA expression at initial diagnosis was associated with a lower CR rate after induction chemotherapy, with only 55.2% (16/29) of LRP-positive acute leukemia patients achieving CR, compared to 82.9% (29/35) of LRP-negative patients achieving CR (p=0.02). Similarly, for AML patients, 47.1% (8/17) of LRP-positives achieved CR, while 82.4% (14/17) of LRP-negatives achieved CR (p=0.03). MDR1 and MRP mRNA expression appeared to have statistically no significant effect on patient outcome following induction chemotherapy. However, MDR1 or MRP mRNA-positive patients showed the tendency of lower CR rates than MDR1 or MRP-negative patients (Table 3). MDR1, MRP or LRP mRNA expression had no effect on relapse rates. The multivariate logistic regression analysis of age, MDR mRNA expression and cytogenetic results indicated that the MDR mRNA expression did not give significant effects on relapse and continuous CR after induction chemotherapy.
###end p 21
###begin p 22
###xml 58 61 58 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 115 118 115 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 269 275 269 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 339 340 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 350 353 350 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 360 361 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier analysis showed that the median survival for MRP-positive acute leukemia patients was 600 days, while MRP-negative patients did not reach the median survival time. There was a significant difference in the 2-yr survival between these two groups (p=0.049) (Fig. 2). There was statistically no prognostic significance for MDR1 (p=0.05) or LRP mRNA (p=0.08) expression in acute leukemic patients in total, nor for AML or ALL patients when analyzed separately.
###end p 22
###begin p 23
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 124 130 124 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
High level MDR1 mRNA expression was significantly associated with poorer 2-yr survival in acute leukemia patients (p=0.04) (Fig. 3), with all three such patients dying within 2 yr (20 days, 228 days and 405 days) of diagnosis. Among these patients, two were diagnosed with adult AML and one with childhood AML. Only one of these three patients achieved CR after induction chemotherapy.
###end p 23
###begin p 24
###xml 61 64 61 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 69 72 69 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
While the survival time appeared to decrease with increasing MRP and LRP mRNA expression levels, this observation was not supported by statistical analysis.
###end p 24
###begin title 25
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Outcome in acute leukemia patients expressing two MDR genes
###end title 25
###begin p 26
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 31 34 31 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 112 115 112 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 120 123 120 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 144 148 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 153 156 153 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 202 205 202 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 270 273 270 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 278 281 278 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 362 363 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 396 399 396 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 414 418 414 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 423 426 423 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 529 532 529 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 537 540 537 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 710 711 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 735 739 735 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 744 747 744 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 766 769 766 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 590 598 <span type="species:ncbi:9606">patients</span>
Double positivity for MDR1 and MRP mRNA was detected in 17 samples (23.4%), MDR1 and LRP mRNA in 15 (21.1%) and MRP and LRP mRNA in 31 (43.7%). MDR1 and LRP positive patients also showed positivity for MRP. While 57.1% (16/28) of acute leukemia patients expressing both MRP and LRP mRNA achieved CR, 80.6% (29/36) of those not expressing both genes achieved CR (p=0.04). Expressing both MDR1 and MRP mRNA, or both MDR1 and LRP mRNA had no significant influence on the CR rate after induction chemotherapy. The median survival of MRP and LRP-double positive patients was 405 days; the other patients did not reach median survival. There was a significant difference in the 2-yr survival between the two groups (p=0.04). Expressing both MDR1 and MRP mRNA, or MDR1 and LRP mRNA had no negative impact on 2-yr survival.
###end p 26
###begin title 27
DISCUSSION
###end title 27
###begin p 28
###xml 33 36 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 256 260 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 264 267 264 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 321 324 321 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 378 381 378 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 413 414 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 433 436 433 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 681 684 681 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 534 542 <span type="species:ncbi:9606">patients</span>
The present study indicates that MDR gene expression can affect outcomes in acute leukemia patients. LRP gene expression at diagnosis appeared to be associated with resistance to induction chemotherapy in acute leukemia patients. This was not the case for MDR1 or MRP gene expression. For AML patients, while over 80% of LRP-negative subjects achieved CR, less than half of the LRP-positive subjects achieved CR (p=0.03). Therefore, LRP mRNA expression was particularly influential in outcomes following induction chemotherapy in AML patients. This correlation between LRP expression and treatment outcome is consistent with suggestions that chemosensitive leukemic cells have low LRP mRNA levels in AML (10, 13).
###end p 28
###begin p 29
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
Interestingly, it was reported that LRP mRNA expression more strongly correlated with drug resistance than LRP protein expression (14). Sauerbrey et al. (15) suggested that LRP overexpression might be a mechanism involved in childhood ALL drug resistance. While the present data appeared to suggest LRP-positive ALL patients showed a lower probability for first remission, this observation was not supported statistically.
###end p 29
###begin p 30
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 768 772 768 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 826 830 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 973 977 973 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 392 400 <span type="species:ncbi:9606">patients</span>
###xml 549 557 <span type="species:ncbi:9606">patients</span>
###xml 747 755 <span type="species:ncbi:9606">patients</span>
###xml 908 916 <span type="species:ncbi:9606">patients</span>
###xml 954 962 <span type="species:ncbi:9606">patients</span>
In AML patients, PGP/MDR1 expression was found to be an independent prognostic variable associated with reduced probability for achieving remission following conventional anthracene-containing induction regimens, and in some reports this expression was linked to inferior leukemia-free and overall survivals (16-18). However, while our data appeared to suggest that MDR1-positive AML and ALL patients had low CR rates and poor 2-yr survivals, this observation was not supported by statistical analysis. It may be that analysis of a larger number of patients would provide the statistical power for significance. The different sensitivities of the detection techniques may be responsible for the discrepant statistical significance. However, three patients with strong MDR1 mRNA expression died within 2 yr, and high levels of MDR1 mRNA were significantly associated with poor 2-yr survival in acute leukemia patients. Therefore, we need to consider that patients with high MDR1 mRNA expression may have poorer outcomes.
###end p 30
###begin p 31
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 245 248 245 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 313 316 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 336 337 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 146 153 <span type="species:ncbi:9606">patient</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
The reported proportion of patients positive for MDR gene expression varies widely and appears to be related to the study method employed and the patient characteristics of any particular study. In the present study, 83.1% of patients expressed MRP mRNA, and 2-yr survival in these patients was less than that in MRP-negative patients (p=0.049). Although some studies show MRP expression lacked prognostic power (19, 20), others found it was predictive of poorer outcome (21).
###end p 31
###begin p 32
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 310 313 310 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
In the present study, MRP and LRP-double positive patients showed reduced remission rates after induction chemotherapy and poorer 2-yr overall survival compared to patients not expressing both of these genes. Only two studies have previously attempted to determine the impact of simultaneous expression of two MDR genes, and the conclusions drawn by these studies were not consistent with each other (21, 22).
###end p 32
###begin p 33
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 116 119 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 124 127 124 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 161 164 161 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 169 172 169 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 266 269 266 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
The present study demonstrates that outcomes in acute leukemia patients can vary depending upon expression of MDR1, MRP and LRP mRNA. Simultaneous expression of MRP and LRP mRNA correlated with a low CR rate and poor survival. These results suggest that analysis of MDR gene expression at diagnosis of acute leukemia may provide useful prognostic information. Such data is also likely to assist in determining the mechanisms underlying drug resistance.
###end p 33
###begin article-title 34
Genetic and biochemical characterization of multidrug resistance
###end article-title 34
###begin article-title 35
Multidrug resistance in leukaemia
###end article-title 35
###begin article-title 36
###xml 24 29 <span type="species:ncbi:9606">human</span>
Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins
###end article-title 36
###begin article-title 37
Relation among the tests and comparison of positivity of tests for multi-drug resistance in newly diagnosed acute leukemia
###end article-title 37
###begin article-title 38
Drug resistance mechanisms in acute leukemia
###end article-title 38
###begin article-title 39
Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene
###end article-title 39
###begin article-title 40
Overexpression of a M (r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
###end article-title 40
###begin article-title 41
Reversal of multidrug resistance of tumor cells
###end article-title 41
###begin article-title 42
Expression of multidrug resistance-related genes does not contribute to risk factors in newly diagnosed childhood acute lymphoblastic leukemia
###end article-title 42
###begin article-title 43
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
###end article-title 43
###begin article-title 44
P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study
###end article-title 44
###begin article-title 45
Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India
###end article-title 45
###begin article-title 46
###xml 76 84 <span type="species:ncbi:9606">patients</span>
High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone
###end article-title 46
###begin article-title 47
###xml 94 99 <span type="species:ncbi:9606">human</span>
Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines
###end article-title 47
###begin article-title 48
Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia
###end article-title 48
###begin article-title 49
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry
###end article-title 49
###begin article-title 50
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
###end article-title 50
###begin article-title 51
MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia
###end article-title 51
###begin article-title 52
###xml 165 172 <span type="species:ncbi:9606">patient</span>
Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival
###end article-title 52
###begin article-title 53
Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia
###end article-title 53
###begin article-title 54
Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
###end article-title 54
###begin article-title 55
Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia
###end article-title 55
###begin p 56
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 40 43 40 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 307 308 307 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</italic>
###xml 335 338 335 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 427 430 427 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
###xml 197 204 <span type="species:ncbi:9606">patient</span>
###xml 318 325 <span type="species:ncbi:9606">patient</span>
###xml 440 447 <span type="species:ncbi:9606">patient</span>
RT-PCR products following MDR1, MRP and LRP mRNA amplification. Lane S, size marker; lane 1, MDR1-positive cell line (band at 243 bp); lane 2, DW; lane 3, normal bone marrow; lane 4, MDR1-positive patient; lane 5, MRP-positive line (bands at 575 and 420 bp); lane 6, DW; lane 7, normal bone marrow; lane 8, s-positive patient; lane 9, LRP-positive cell line (band at 239 bp); lane 10, DW; lane 11, normal bone marrow; lane 12, LRP-positive patient; lane 13, beta-actin (internal control, band at l66 bp). (DW=deionized water (negative control)).
###end p 56
###begin p 57
###xml 21 24 21 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Relationship between MRP mRNA expression and 2-yr survival in acute leukemia patients.
###end p 57
###begin p 58
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Relationship between MDR1 mRNA expression levels and 2-yr survival in acute leukemia patients.
###end p 58
###begin p 59
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRP</italic>
###xml 39 42 39 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP</italic>
RT-PCR primer sequences for MDR1, MRP, LRP and beta-actin mRNA amplification
###end p 59
###begin p 60
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Semiquantitative MDR gene expression results in acute leukemia patients
###end p 60
###begin p 61
###xml 21 24 21 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
Relationship between MDR gene expression at acute leukemia diagnosis and complete remission (CR) and relapse rates after induction chemotherapy
###end p 61
###begin p 62
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
*p value <0.05; CR, complete remission.
###end p 62

